Sanofi (NASDAQ: SNY) is a Healthcare company in the Drug Manufacturers - General industry. QuoTrend tracks its price, financials, earnings, analyst ratings and insider trades.
| Index | - | P/E | 23.03 | EPS (ttm) | 1.89 | Insider Own | - | Shs Outstand | 2.40B | Perf Week | 0.88% |
| Market Cap | 104.53B | Forward P/E | 8.42 | EPS next Y | 5.16 | Insider Trans | - | Shs Float | 2.17B | Perf Month | -1.00% |
| Enterprise Value | 124.44B | PEG | - | EPS next Q | 2.03 | Inst Own | - | Short Float | 0.34% | Perf Quarter | 0.65% |
| Income | 4.59B | P/S | 1.85 | EPS this Y | 732.44% | Inst Trans | - | Short Ratio | 2.32 | Perf Half Y | -8.49% |
| Sales | 56.55B | P/B | 1.30 | EPS next Y | 6.93% | ROA | 3.07% | Short Interest | 7.37M | Perf YTD | -10.32% |
| Book/sh | - | P/C | 5.22 | EPS next 5Y | 8.65% | ROE | 5.52% | 52W High | 52.70 -17.50% | Perf Year | -5.89% |
| Cash/sh | - | P/FCF | 5.49 | EPS past 3/5Y | 2.58% -8.40% | ROIC | 7.41% | 52W Low | 40.91 6.29% | Perf 3Y | -15.60% |
| Dividend Est. | 2.42 (5.56%) | EV/EBITDA | 13.05 | Sales past 3/5Y | 7.30% 4.34% | Gross Margin | 72.77% | Volatility | 1.50% 1.63% | Perf 5Y | -15.71% |
| Dividend TTM | 2.42 (5.56%) | EV/Sales | 2.20 | EPS Y/Y TTM | -75.52% | Oper. Margin | 20.58% | ATR (14) | 0.98 | Perf 10Y | 2.02% |
| Dividend Ex-Date | May 04, 2026 | Quick Ratio | 0.23 | Sales Y/Y TTM | 19.10% | Profit Margin | 8.09% | RSI (14) | 50.19 | Recom | 2.59 |
| Dividend Gr. 3/5Y | 2.41% 4.60% | Current Ratio | 0.99 | EPS Q/Q | 18.64% | SMA20 | -0.44% | Beta | 0.31 | Target Price | 49.50 |
| Payout | 124.38% | Debt/Eq | 0.34 | Sales Q/Q | 17.52% | SMA50 | 0.23% | Rel Volume | 0.81 | Prev Close | 43.46 |
| Employees | 76,493 | LT Debt/Eq | 0.22 | Earnings | Oct 23 | SMA200 | -6.21% | Avg Volume | 3.42M | Price | 43.48 |
| IPO Date | Jul 01, 2002 | Option/Short | Yes / Yes | EPS/Sales Surpr. | 9.16% 9.61% | Net Debt/EBITDA | 2.09 | Volume | 2,756,617 | Change | 0.05% |
| Date | Action | Analyst | Rating | Target |
|---|---|---|---|---|
| Jul-08-26 | Reiterated | Morgan Stanley | Equal Weight | $52 → $49 |
| May-01-26 | Downgrade | Morgan Stanley | Overweight → Equal Weight | $56 → $52 |
| Apr-20-26 | Reiterated | BNP Paribas | $50 | |
| Apr-20-26 | Downgrade | Exane BNP Paribas | Outperform → Neutral | |
| Feb-12-26 | Downgrade | B of A Securities | Buy → Neutral | |
| Jan-16-26 | Downgrade | UBS | Buy → Neutral | |
| Jan-06-26 | Downgrade | Barclays | Overweight → Equal Weight | |
| Dec-09-25 | Downgrade | Guggenheim | Buy → Neutral | |
| Dec-08-25 | Downgrade | JP Morgan | Overweight → Neutral | |
| Sep-08-25 | Upgrade | Morgan Stanley | Equal Weight → Overweight |
Sanofi operates as a leading global pharmaceutical enterprise, dedicated to the research, development, production, and distribution of a wide array of therapeutic solutions across the United States, Europe, and numerous international markets. The company strategically organizes its operations into three core divisions: Pharmaceuticals, Vaccines, and Consumer Healthcare. Within its Pharmaceutical segment, Sanofi delivers specialized therapies, including innovative human monoclonal antibodies, addressing complex conditions like multiple sclerosis, various neurological disorders, immunology and inflammatory diseases, oncology, rare diseases, and rare blood disorders. This segment also encompasses treatments for diabetes, cardiovascular health, and established prescription medications. Its Vaccine portfolio is extensive, offering essential immunizations such as pediatric vaccines for poliomyelitis, pertussis, and Hib, alongside influenza shots, adult boosters, meningitis vaccines, and solutions for travel and endemic diseases. The Consumer Healthcare division provides a broad spectrum of over-the-counter products, including remedies for allergies, coughs and colds, pain management, liver support, physical and mental wellness, probiotics, digestive health aids, and nutritional supplements. Additionally, it offers various personal care items like daily body lotions, anti-itch creams, moisturizing and soothing lotions, body and foot creams, and specialized powders for eczema. Sanofi maintains a robust development pipeline, with numerous pharmaceutical products and vaccines currently in various stages of research. The company actively pursues strategic alliances, exemplified by its collaboration with GlaxoSmithKline on a recombinant Covid-19 vaccine, a research partnership with Stanford University School of Medicine focused on advancing immunology and inflammation understanding, and a collaboration and license option agreement with Prellis Biologics, Inc. Founded in 1973 and headquartered in Paris, France, the company was formerly known as Sanofi-Aventis before officially changing its name to Sanofi in May 2011.
Per-holder 13F data hasn't been ingested for this ticker yet.
| Line Item (USD, M) | TTM — | FY 2025 12/31/2025 | FY 2024 12/31/2024 | FY 2023 12/31/2023 | FY 2022 12/31/2022 | FY 2021 12/31/2021 | FY 2020 12/31/2020 | FY 2019 12/31/2019 | FY 2018 12/31/2018 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | 57,066 | 52,702 | 47,913 | — | — | — | — | — | — | |
| Cost of Goods Sold Incl. D&A | 15,395 | 14,721 | 14,286 | — | — | — | — | — | — | |
| Gross Profit | 41,670 | 37,981 | 33,626 | — | — | — | — | — | — | |
| Selling, General and Administrative Excl. Other | 11,453 | 11,554 | 9,935 | — | — | — | — | — | — | |
| Research and Development | 9,452 | 8,847 | 8,000 | — | — | — | — | — | — | |
| Other Operating Expense | 12,311 | 6,753 | 7,845 | — | — | — | — | — | — | |
| Operating Income | 8,453 | 10,827 | 7,846 | — | — | — | — | — | — | |
| Interest Expense | 690 | 706 | 674 | — | — | — | — | — | — | |
| Unusual Expense | — | — | — | — | — | — | — | — | — | |
| Non-Operating Income (Expense) | -1,687 | -3,329 | 139 | — | — | — | — | — | — | |
| Net Income Before Taxes | 6,076 | 6,791 | 7,311 | — | — | — | — | — | — | |
| Income Taxes | 1,406 | 1,177 | 1,303 | — | — | — | — | — | — | |
| Consolidated Net Income | 4,631 | 8,814 | 6,015 | — | — | — | — | — | — | |
| Net Income From Continuing Operations | 4,670 | 5,615 | 6,009 | — | — | — | — | — | — | |
| Net Income | 4,631 | 8,814 | 6,015 | — | — | — | — | — | — | |
| EPS (Recurring) | 0.57 | 3.61 | 2.37 | — | — | — | — | — | — | |
| EPS (Basic, Before Extraordinaries) | 0.57 | 3.61 | 2.37 | — | — | — | — | — | — | |
| EPS (Diluted) | 0.58 | 3.61 | 2.37 | — | — | — | — | — | — | |
| EBITDA | 14,486 | 14,078 | 11,937 | — | — | — | — | — | — | |
| Other After Tax Adjustments | — | — | — | — | — | — | — | — | — | |
| Stock Option Compensation Expense | — | — | — | — | — | — | — | — | — | |
| Price To Earnings Ratio | 74.97 | 13.42 | 20.36 | — | — | — | — | — | — | |
| Price To Sales Ratio | 1.82 | 2.24 | 2.52 | — | — | — | — | — | — | |
| Gross Margin | 73.02 | 72.07 | 70.18 | — | — | — | — | — | — | |
| Operating Margin | 14.81 | 20.54 | 16.38 | — | — | — | — | — | — | |
| Net Margin | 8.12 | 16.72 | 12.55 | — | — | — | — | — | — | |
| Shares Outstanding | 2,393 | 2,441 | 2,503 | — | — | — | — | — | — | |
| Market Capitalization | 104,048 | 118,291 | 120,720 | — | — | — | — | — | — | |
| Operating Lease Expense | — | — | — | — | — | — | — | — | — |